BioXcel Therapeutics, Inc. cash flow to debt ratio of -52.54% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

BioXcel Therapeutics, Inc.'s free cash flow has increased -20.01% from $-72.03M last year to $-57.62M, signaling increasing performance

BioXcel Therapeutics, Inc.'s debt to equity ratio is -0.95, signaling that the company spent its equity and risk bankruptcy.

BioXcel Therapeutics, Inc.'s debt to equity ratio is -0.95, signaling that the company spent its equity and risk bankruptcy.

BioXcel Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

BioXcel Therapeutics, Inc.'s interest coverage ratio is -2.93, which means that the company struggles to meet interest obligations, signaling financial risk.

BioXcel Therapeutics, Inc.'s profit margin has decreased (321.21%) in the last year from -2.63K% to -11.08K%, signaling decreasing performance

BioXcel Therapeutics, Inc.'s short-term liabilities of $53.93M exceed its short-term assets of $44.69M, signaling financial risk

BioXcel Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioXcel Therapeutics, Inc.'s return on equity of 75.79%, is higher than 15.00%, indicating good performance

BioXcel Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioXcel Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

BioXcel Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

BioXcel Therapeutics, Inc. has negative free cash flow, indicating cash burn

BioXcel Therapeutics, Inc.'s yearly earnings has decreased 17.28% since last year from $-59.60M to $-69.90M, signaling decreasing performance

BioXcel Therapeutics, Inc.'s yearly revenue has decreased 71.67% since last year from $2.27M to $642.00K, signaling decreasing performance

ROIC -3.44K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioXcel Therapeutics, Inc.'s 3-year revenue CAGR of 19.63% is positive, indicating growing revenue over the past 3 years

BioXcel Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

BioXcel Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioXcel Therapeutics, Inc. has insufficient data to evaluate this check.

BioXcel Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioXcel Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

BioXcel Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioXcel Therapeutics, Inc. has insufficient data to evaluate this check.

BioXcel Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioXcel Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

BioXcel Therapeutics, Inc. has a price-to-sales ratio of 16.66x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue